Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy

Deborah A. DeManno, Deborah DeManno, DeManno D, W Elger, Walter Elger, Elger W, Ramesh C. Garg, Garg R, Ramesh Garg, Lee R, Ronald Lee, Birgitt Schneider, Schneider B, Holger Hess-Stumpp, Hess-Stumpp H, Holger Hess‐Stumpp, Schubert G, Gerd Schubert, G. Schubert, Kristof Chwalisz, Chwalisz K, Kristof Chwalisż
Steroids · 2003 · vol. 68(10-13) , pp. 1019–1032 · doi:10.1016/j.steroids.2003.09.008 · PMID:14667995 · W2086270483
review OA: closed CC0 ⤵ 25 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-10 ⓘ

Asoprisnil (J867) is a selective progesterone receptor modulator developed for gynecological therapy.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Asoprisnil is a novel selective steroid receptor modulator that shows unique pharmacodynamic effects in animal models and humans. Asoprisnil, its major metabolite J912, and structurally related compounds represent a new class of progesterone receptor (PR) ligands that exhibit partial agonist and antagonist activities in vivo. Asoprisnil demonstrates a high degree of receptor and tissue selectivity, with high-binding affinity for PR, moderate affinity for glucocorticoid receptor (GR), low affinity for androgen receptor (AR), and no binding affinity for estrogen or mineralocorticoid receptors. In the rabbit endometrium, both asoprisnil and J912 induce partial agonist and antagonist effects. Asoprisnil induces mucification of the guinea pig vagina and has pronounced anti-uterotrophic effects in normal and ovariectomized guinea pigs. Unlike antiprogestins, asoprisnil shows only marginal labor-inducing activity during mid-pregnancy and is completely ineffective in inducing preterm parturition in the guinea pig. Asoprisnil exhibits only marginal antiglucocorticoid activity in transactivation in vitro assays and animal models. In male rats, asoprisnil showed weak androgenic and anti-androgenic properties. In toxicological studies in female cynomolgus monkeys, asoprisnil treatment abolished menstrual cyclicity and endometrial atrophy. Early clinical studies of asoprisnil in normal volunteers demonstrated a dose-dependent suppression of menstruation irrespective of the effects on ovulation, with no change in basal estrogen concentrations and no antiglucocorticoid effects. Unlike progestins, asoprisnil does not induce breakthrough bleeding. With favorable safety and tolerability profiles thus far, asoprisnil appears promising as a novel treatment of gynecological disorders, such as uterine fibroids and endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Oximes Oxytocics Receptors, Progesterone Animals Endometriosis Endometriosis Endometrium Endometrium Estrenes Female Guinea Pigs Humans Leiomyoma Leiomyoma Ligands Macaca fascicularis Male Models, Chemical Oximes Oxytocics

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (12)

Cited by (26)

Source provenance

europepmc
last seen: 2026-09-06T09:34:12.023084+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:44.121522+00:00
unpaywall
last seen: 2026-09-06T06:31:40.515551+00:00
License: CC0 · commercial use OK